Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Next Previous
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisolone; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Cougar Biotechnology; Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 06 Jun 2023 Results of Secondary post-hoc sub-analyses of two randomized clinical trials (NCT00887198, n = 1088 and NCT02257736, n = 982) assessing The association between antibiotics administration and outcomes in men with chemotherapy-naive metastatic castration-resistant prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 01 Jun 2023 Results a Secondary Analysis of the COU-AA-302 trial assessing the receipt of prior prostate-directed LT influenced the response to first-line systemic therapy and survival in docetaxel-naive metastatic castrate-resistant prostate cancer (mCRPC) patients published in the European Urology
  • 16 May 2023 Results of meta-analysis from PROpel , PREVAIL and COU-AA-302 (AA) treatment arms, Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer, published in the European Urology Open Science

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top